Compare Merck & Co., Inc. (MRK) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Vale SA — how do they compare? Merck & Co., Inc. trades at $142.03 (market cap $351.28B), while Vale SA trades at $13.6 (market cap $57.32B). The key difference: Merck & Co., Inc. is far larger — about 6.1× Vale SA's market cap, and Vale SA pays the higher dividend (8.87%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Vale SA for 109 Days on average.
| MRK | VALE | |
|---|---|---|
Market Cap | $351.28B | $57.32B |
Volume | 7,969,665 | 27,996,846 |
Sector | Health | Basic Materials |
52-Week High | $156.43 | $17.82 |
52-Week Low | $82.49 | $10.75 |
Typical Hold Time | 98 Days | 109 Days |
Enterprise Value | $398.04B | $73.56B |
Dividend Yield | 2.39% | 8.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% today, with a bearish technical signal but strong fundamental performance. The company reported revenue of $65.01B in 2025 with a net income margin of 28.07%, and recent quarterly EPS have consistently beaten expectations. Merck is actively expanding its pipeline through acquisitions, such as the pending $6.7B purchase of Terns Pharmaceuticals announced in April 2026.
The outlook is supported by solid profitability and analyst optimism, with a consensus price target of $158.78 implying upside. Key risks include integration challenges from acquisitions and competitive pressures in the oncology sector. Cash flow trends show variability, with a projected net cash outflow of $1.2B in 2026 due to significant investing activities.
VALE trades at $13.61, down 3.34% amid broader market weakness in mining stocks. The stock shows bearish technical signals with recent earnings misses and declining profit margins (5.11% net margin in 2025). Revenue has stabilized around $38-41B, but iron ore pricing pressure and rising costs challenge near-term profitability. Analyst consensus remains mixed with 32% buy ratings despite a $16.21 price target suggesting 19% upside potential.
The investment case balances Vale's position as a low-cost iron ore producer against cyclical commodity exposure and Brazilian regulatory risks. Base metals growth provides diversification, but margin compression and debt increases warrant caution. Current valuation at 27x P/E appears stretched given earnings volatility, making risk-reward balanced for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
